Literature DB >> 29984390

Raised plasma levels of H2S and nitrate predict intrapulmonary vascular dilations: A preliminary report in patients with cryptogenic cirrhosis.

Chinmay Bera1, Kavitha Thangaraj2, Purendra Kumar Pati3, Jeyamani Ramachandran1, K A Balasubramanian2, Anup Ramachandran2, Uday Zachariah1, K G Sajith1, Ashish Goel1, C E Eapen4.   

Abstract

BACKGROUND AND AIMS: The role of vasoactive chemicals in the pathogenesis of hepatopulmonary syndrome (HPS), a disorder characterized by intrapulmonary vascular dilation (IPVD), is only vaguely elucidated. We aimed to study the association between plasma H2S, nitrate levels, and presence and severity of IPVD and HPS.
METHODS: Consecutive adult patients with cryptogenic cirrhosis were evaluated for IPVD (by contrast echocardiography) and for hypoxemia (by arterial blood gas analysis). Plasma H2S and nitrate levels were measured in these patients.
RESULTS: Fifty-eight patients with cryptogenic cirrhosis (male, 45; median age, range, 45, 16-74 years; Child's class; A, 30; B, 18; C, 10) were enrolled in this study. Thirty-four of the 58 (59%) patients had IPVD and 13 (22%) had HPS (mild, 4; moderate, 5; severe, 2; very severe, 2). Plasma H2S levels were significantly higher in patients with IPVD (19.6, 5.7-83 μmol/L) as compared to patients who had no IPVD (12.3, 0-47 μmol/L; p-value 0.03) with an area under receiver operating characteristic curve of 0.68 (95% CI 0.53-0.84). Plasma H2S levels were higher in patients with IPVD irrespective of liver disease severity. There was a trend for higher plasma nitrate levels in patients with IPVD (47, 15.8-126.4 nmol/mL) as compared to patients who had no IPVD (32.3, 6.9-51.4 nmol/mL; p-value 0.1). Raised plasma H2S and nitrate levels had an additive effect on the presence of IPVD. Neither plasma H2S nor plasma nitrate levels correlated with the degree of hypoxemia.
CONCLUSION: Raised plasma H2S and nitrate levels predict the presence of IPVD in patients with cryptogenic cirrhosis.

Entities:  

Keywords:  Hepatopulmonary syndrome; Nitric oxide; Sulfate

Mesh:

Substances:

Year:  2018        PMID: 29984390     DOI: 10.1007/s12664-018-0862-9

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  26 in total

1.  Sulfate-reducing bacteria impairs working memory in mice.

Authors:  Nathaniel L Ritz; Benjamin J Burnett; Prashanth Setty; Katelyn M Reinhart; Melissa R Wilson; Joe Alcock; Sudha B Singh; Larry L Barton; Henry C Lin
Journal:  Physiol Behav       Date:  2016-02-06

2.  The role of hemodynamic and vasoactive substances on hepatopulmonary syndrome.

Authors:  G Feng; H Rong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

Review 3.  Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis.

Authors:  M R Ebrahimkhani; A R Mani; K Moore
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

4.  Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography.

Authors:  R Aller; J L Moya; V Moreira; D Boixeda; A Cano; J Picher; S García-Rull; D A de Luis
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 5.  Hydrogen sulphide and angiogenesis: mechanisms and applications.

Authors:  Csaba Szabó; Andreas Papapetropoulos
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome.

Authors:  Miguel R Arguedas; Britt B Drake; Ashwani Kapoor; Michael B Fallon
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

Review 7.  Nitric oxide in liver diseases.

Authors:  Yasuko Iwakiri; Moon Young Kim
Journal:  Trends Pharmacol Sci       Date:  2015-05-28       Impact factor: 14.819

Review 8.  Hydrogen sulfide and the liver.

Authors:  Sarathi Mani; Wei Cao; Lingyun Wu; Rui Wang
Journal:  Nitric Oxide       Date:  2014-02-26       Impact factor: 4.427

9.  The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Andrea Mencarelli; Stefano Orlandi; Barbara Renga; Giovanni Rizzo; Eleonora Distrutti; Vijay Shah; Antonio Morelli
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

10.  Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome.

Authors:  Anne Rabiller; Hilario Nunes; Didier Lebrec; Khalid A Tazi; Myriam Wartski; Elisabeth Dulmet; Jean-Marie Libert; Christine Mougeot; Richard Moreau; Michel Mazmanian; Marc Humbert; Philippe Hervé
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.